Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study

Blood blood.2024024657.

https://doi.org/10.1182/blood.2024024657

Published: 2024

Includes: Supplemental data

Journal Articles

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Blood (2023) 142 (Supplement 1): 865.

https://doi.org/10.1182/blood-2023-172583

Published: 2023

Journal Articles

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Blood (2016) 128 (22): 939.

https://doi.org/10.1182/blood.V128.22.939.939

Published: 2016

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2016) 128 (22): 646.

https://doi.org/10.1182/blood.V128.22.646.646

Published: 2016

Journal Articles

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)

Blood (2015) 126 (23): 815.

https://doi.org/10.1182/blood.V126.23.815.815

Published: 2015

Journal Articles

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Blood (2015) 125 (6): 915–923.

https://doi.org/10.1182/blood-2014-07-590315

Published: 2015

Includes: Supplemental data

Journal Articles

Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Patricia A. Walker, MBBS, FRACP, FRCPA, Tiffany T. Khong, BSc, PhD, Anthony Schwarer, MD, Andrew W. Roberts, MBBS, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Robin Filshie, PhD FRACP, Angela Smiley, Malgorzata Gorniak, Marion Black, Nicole Jenkins, Geoffrey Raines, Andrew Spencer, MBBS FRACP FRCPA MD

Blood (2014) 124 (21): 2103.

https://doi.org/10.1182/blood.V124.21.2103.2103

Published: 2014

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2014) 124 (21): 35.

https://doi.org/10.1182/blood.V124.21.35.35

Published: 2014

Journal Articles

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

David T Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD, Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, MBChB, FRACP, FRCPA, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2012) 120 (21): 3771.

https://doi.org/10.1182/blood.V120.21.3771.3771

Published: 2012

Journal Articles

All- trans -retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Blood (2012) 120 (8): 1570–1580.

https://doi.org/10.1182/blood-2012-02-410746

Published: 2012

Journal Articles

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD. FFSc(RCPA), Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA

Blood (2011) 118 (21): 451.

https://doi.org/10.1182/blood.V118.21.451.451

Published: 2011

Journal Articles

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD, Susan Branford, PhD, Lauren Haswell, MSci, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K. Hiwase, MBBS, PhD, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K. Arthur, MBBS, Yiu Lam Kwan, MBBS, FRACP, FRCPA, Cecily J. Forsyth, FRACP, FRCPA, David M. Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2010) 116 (21): 209.

https://doi.org/10.1182/blood.V116.21.209.209

Published: 2010

Journal Articles

The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).

Melita K Kenealy, MBBS, FRACP, FRCPA, John F Seymour, MBBS, PhD, FRACP, Cowan Linda, Alvin Milner, Pratyush Giri, Shir-Jing Ho, MBBS, FRACP, FRCPA, Warwick Benson, Andrew Nicol, MBBS, FRCPA, FRACP, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Ian Prosser, MBBS, FRACP, FRCPA, PhD, Craig Underhill, MBBS, FRACP, Ilona Cunningham, Anthony K. Mills, MBBS, FRACP, FRCPA, Jeffrey Szer, MBBS, FRACP, Peter Presgrave, MBBS, FRACP, FRCPA, PhD, Robin Filshie, MBChB, FRACP, FRCPA, PhD

Blood (2009) 114 (22): 1749.

https://doi.org/10.1182/blood.V114.22.1749.1749

Published: 2009

Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Blood (2009) 114 (22): 1125.

https://doi.org/10.1182/blood.V114.22.1125.1125

Published: 2009

Journal Articles

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Davi D M Ross, Andrew Grigg, Anthony Schwarer, Christopher Arthur, Kerryn Loftus, Anthony K Mills, Robin Filshie, Ruth Columbus, John Reynolds, John F Seymour, MB, BS, PhD, FRACP, Susan Branford, Timothy Hughes

Blood (2008) 112 (11): 1102.

https://doi.org/10.1182/blood.V112.11.1102.1102

Published: 2008

Journal Articles

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Blood (2008) 112 (10): 3965–3973.

https://doi.org/10.1182/blood-2008-06-161737

Published: 2008

Includes: Supplemental data

Journal Articles

Significant Reduction of BCR-ABL Transcripts after Switching to Imatinib Therapy in Patients with CML and Complete or Near-Complete Cytogenetic Responses to Interferon-Alpha (IFN).

Susan Branford, Timothy Hughes, Steven Stylian, Anthony P. Schwarer, Chris Arthur, Robin Filshie, Susan Moreton, Robyn Rodwell, Nancy Guzzo-Pernell, Deb Taylor, Jenny Larson, Rachel Koelmayer, Alvin Milner, Kevin Lynch, Kerry McDonald Taylor

Blood (2006) 108 (11): 2142.

https://doi.org/10.1182/blood.V108.11.2142.2142

Published: 2006

Journal Articles

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

Timothy P. Hughes, Susan Branford, John Reynolds, Rachel Koelmeyer, John Seymour, Kerry Taylor, Nancy Guzzo-Pernell, Robin Filshie, Chris Arthur, Anthony Schwarer, Mark Hertzberg, Michael Copeman, Kevin Lynch, Andrew Grigg

Blood (2005) 106 (11): 164.

https://doi.org/10.1182/blood.V106.11.164.164

Published: 2005

Journal Articles

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Susan Branford, Zbigniew Rudzki, Ian Parkinson, Andrew Grigg, Kerry Taylor, John F. Seymour, Simon Durrant, Peter Browett, Anthony P. Schwarer, Chris Arthur, John Catalano, Michael F. Leahy, Robin Filshie, Kenneth Bradstock, Richard Herrmann, David Joske, Kevin Lynch, Tim Hughes

Blood (2004) 104 (9): 2926–2932.

https://doi.org/10.1182/blood-2004-03-1134

Published: 2004

NARROW

Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

All- trans -retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Significant Reduction of BCR-ABL Transcripts after Switching to Imatinib Therapy in Patients with CML and Complete or Near-Complete Cytogenetic Responses to Interferon-Alpha (IFN).

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only